摘要
目的:探讨富马酸喹硫平与氟哌啶醇对精神分裂症患者的影响。方法:选取2019年10月-2020年10月泉州市第三医院收治的80例精神分裂症患者。按就诊顺序编号进行分组,奇数编号为对照组,偶数编号为观察组,各40例。入院后对全部患者采取常规综合治疗措施,对照组在此基础上给予氟哌啶醇片,观察组给予富马酸喹硫平片。比较两组治疗前后生存质量、精神症状情况及不良反应。结果:治疗前两组生存质量测定量表(WHOQOL-100)、阳性与阴性症状量表(PANSS)评分比较差异均无统计学意义(P>0.05),治疗后观察组WHOQOL-100评分高于对照组,PANSS评分低于对照组(P<0.05)。观察组不良反应发生率明显低于对照组(P<0.05)。结论:对精神分裂症患者采取富马酸喹硫平的治疗效果确切,有效改善患者生存质量,有助于减少不良反应风险,值得临床采纳。
Objective:To investigate the effect of Quetiapine Fumarate and Haloperidol on patients with schizophrenia.Method:A total of 80 patients with schizophrenia admitted to the Third Hospital of Quanzhou City from October 2019 to October 2020 were selected.The patients were divided into groups according to the number of treatment order,with odd number as the control group and even number as the observation group,with 40 patients in each group.After admission,all patients were treated with conventional comprehensive treatment.On this basis,the control group was given Haloperidol Tablets,and the observation group was given Quetiapine Fumarate Tablets.Quality of life,psychiatric symptoms condition before and after treatment and adverse reactions were compared between the two groups.Result:Before treatment,there were no significant differences in quality of life scale (WHOQOL-100) and positive and negative symptom scale (PANSS) scores between the two groups (P>0.05).After treatment,WHOQOL-100 score in the observation group was higher than that in the control group,while PANSS score was lower than that in the control group (P<0.05).The incidence of adverse reactions in observation group was significantly lower than that in control group (P<0.05).Conclusion:Quetiapine Fumarate has a definite therapeutic effect on patients with schizophrenia,effectively improves the quality of life of patients,helps to reduce the risk of adverse reactions,and it is worthy of clinical adoption.
作者
连火霞
陈建
占家铣
林世泽
LIAN Huoxia;CHEN Jian;ZHAN Jiaxian;LIN Shize(The Third Hospital of Quanzhou City,Quanzhou 362000,China;不详)
出处
《中外医学研究》
2022年第9期38-41,共4页
CHINESE AND FOREIGN MEDICAL RESEARCH
